Condition (MeSH)
Cone Dystrophy
ClinicalTrials.gov lists 67 trials for Cone Dystrophy or a narrower condition beneath it. MeiraGTx UK II Ltd has the most among industry and government lead sponsors, with 4.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
6 of the 67 trials are tagged with Cone Dystrophy itself; the rest are tagged with a narrower condition beneath it.
When did Cone Dystrophy trials start? (20)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 7
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 7 |
| 2024 | 2 |
| 2023 | 5 |
| 2022 | 1 |
| 2021 | 5 |
| 2020 | 5 |
| 2019 | 4 |
| 2018 | 3 |
| 2017 | 5 |
Showing 10 of 20 earlier years.
No forecast is made for this condition: it averages 3.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 29 months from start to primary completion across 6 trials still running at the 2026-10-09 snapshot; registered median of 24 months across 42 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Cone Dystrophy trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 6 |
| Phase 1/2 | 7 |
| Phase 2 | 3 |
| Phase 2/3 | 1 |
| Phase 3 | 2 |
| Phase 4 | 2 |
| Not applicable | 28 |
| Observational | 18 |
How many Cone Dystrophy trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 11 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 5 |
| Completed | 35 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Cone Dystrophy trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| MeiraGTx UK II Ltd | 4 |
| Beacon Therapeutics | 3 |
| MD Stem Cells | 2 |
| CENTOGENE GmbH Rostock | 1 |
Which drugs are being tested for Cone Dystrophy? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Cannabidiol | 2 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Group 1 cannabidiol (CBD) with silicone ointment | 1 |
| IVL3003 | 1 |
| Matched control | 1 |
| CBD Isolate | 1 |
| rAAV.hCNGA3 | 1 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Cone Dystrophy trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Uveitis | 5 | 2 |
| Post Procedural Hematuria | 4 | 1 |
| Ectopic pregnancy | 2 | 1 |
| Pneumothorax | 2 | 1 |
| Retinal detachment | 2 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Cone Dystrophy? (2)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| ATXN7-Related Cone-Rod Dystrophy: The Integrated Functional Evaluation of the Cerebellum (CERMOI) Study. | JAMA ophthalmology | 2024 | Yes |
| Effectiveness of Low Vision Rehabilitation Using Microperimetric Acoustic Biofeedback Training in Patients with Central Scotoma. | Current eye research | 2021 | No |
Prevalence (1)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Progressive cone dystrophy | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: rare-disease identity.